Yanhong Wang

Yanhong Wang

Auto-generated profile, based on publicly available information

Yanhong Wang

Fudan University, Shanghai, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2024 in Nanoscale
Verified
Journal Article
Closed access
PDF file
CWChao Wang
Chao Wang
YXYutao Xiu
Yutao Xiu
YZYujing Zhang
Yujing Zhang
YWYanhong Wang
Yanhong Wang
JXJiazhen Xu
Jiazhen Xu
DXDongming Xing
Dongming Xing
Biotin receptors, as biomarkers for cancer cells, are overexpressed in various tumor types. Compared to other vitamin receptors, such as folate receptors and vitamin B12 receptors, biotin receptor-based targeting strategies exhibit superior specificity and broader potential in treating aggressive cancers, including ovarian cancer, leukemia, colon cancer, breast cancer, kidney cancer, and lung cancer. These strategies promote biotin transport via receptor-mediated endocytosis, which is triggered upon ligand binding. Biotin, as the ligand of the biotin receptor, can be conjugated to anti-cancer drugs to form targeted therapies that bind to receptors overexpressed on tumor cells, thus increasing drug uptake. Despite these advantages, many candidate drugs have progressed slowly and remain in the preclinical stage, impeding clinical translation. This is mainly due to the effects of various conjugation methods and drug formulations on their functionality and efficacy. Therefore, developing novel biotin-based therapeutics is crucial. The innovation of this strategy lies in its multifunctionality—researchers can use different conjugation methods to design and synthesize these drugs, enabling precise targeting of various tumor types while minimizing toxicity to normal cells. These drugs include small-molecule-biotin conjugates (SMBCs) and nano-biotin conjugates (NBCs). This dual-platform approach represents a significant advancement in targeted therapy, offering unprecedented flexibility in drug design and delivery. Compared to chemotherapy drugs and traditional delivery systems, biotin-based drugs with tumor-specific targeting demonstrate enhanced targeting, improved efficacy, and reduced toxicity. This review examines strategies and applications for enhancing the delivery of chemotherapy drugs to cancer cells, highlighting the need for high-quality conjugates and strategies. It not only summarizes the latest progress but also provides key insights into how this emerging field could revolutionize personalized cancer treatment, especially in the context of precision medicine. Additionally, it offers perspectives on future research directions in this field.

5 June 2025 in ACM Transactions on Embedded Computing Systems
Verified
Journal Article
Open access
ZZZihao Zhao
Zihao Zhao
YWYanhong Wang
Yanhong Wang
XJXu Jin
Xu Jin
HZHaotian Zheng
Haotian Zheng
MNMaohua Nie
Maohua Nie
CSC.-J. Richard Shi
C.-J. Richard Shi
Deep neural networks (DNNs) have proved their great potential over various perceptual and cognitive tasks with the cost of ever-growing storage capacity and computation complexity. Sparse representations in neural networks have emerged as a compelling method to achieve substantial reductions in computational overhead and energy consumption. However, the introduction of sparsity presents challenges such as irregular memory accesses and wasted computation cycles. Traditional methods have attempted to address these challenges with varied success, unfortunately, often involving complex hardware designs or sacrificing sparsity’s benefits. In this article, we propose a software-hardware codesign solution, comprising an offline workload balancing encoding algorithm toward arbitrary sparsity in DNNs and a dedicated Processing Element array–based accelerator with a lightweight switch network. Extensive experiments are conducted to demonstrate the conclusion that our proposal is feasible to support various network structures and a wide range of sparsity ratios. With the encoding algorithm, a 1.16×–2.61× acceleration is achieved compared to the baseline. The system-on-chip measures 7.9 mm 2 , achieving an energy efficiency of 0.7 TOPS/W (dense), 2.1 TOPS/W (at 75% sparsity), and 10.3 TOPS/W (at 99.9% sparsity) at 0.9 V and 1,066-MHz clock frequency.